International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(21), P. 11354 - 11354
Published: Oct. 22, 2024
Molecular
testing
is
recommended
in
patients
with
metastatic
non-small
cell
lung
cancer
(NSCLC),
but
the
extent
of
its
use
Poland
unknown.
The
aim
POL-MOL
study
was
to
investigate
frequency
using
molecular
Polish
NSCLC.
invited
oncologists
completed
two
questionnaires,
and
data
for
1001
undergoing
systemic
treatment
NSCLC
were
collected.
tests
following
genetic
mutations
recorded:
ACS Omega,
Journal Year:
2024,
Volume and Issue:
9(43), P. 43697 - 43705
Published: Oct. 15, 2024
Lung
cancer
is
one
of
the
leading
causes
death.
Celastrol
a
natural
product
that
has
shown
anticancer
activity
but
not
yet
been
applied
in
clinical
settings
due
to
its
narrow
therapeutic
window.
In
this
study,
we
discovered
celastrol
stimulates
an
abnormal
rise
reactive
oxygen
species
(ROS)
level
lung
cells
and
ROS
scavenger
N-acetylcysteine
(NAC)
could
counteract
cell
death
caused
by
celastrol.
At
same
time,
upregulated
expression
cytoprotective
transcription
factor
Nrf2
downstream
proteins,
which
are
effective
preventing
oxidative
damage
accumulation.
Notably,
found
overexpression
enhances
tolerance
H460
with
Keap1
mutation
insensitive
This
indicates
increase
contributes
survival
cells.
Thus,
brought
inhibitor
ML385
suppress
activation
Nrf2.
We
when
were
added
together
rates
decreased
more
detected
became
much
higher
compared
treatment
alone.
also
suppressed
HO-1
GCLC,
amplified
celastrol-induced
ATF4/CHOP-dependent
endoplasmic
reticulum
stress
(ER
stress).
Above
all,
our
study
enhanced
increases
ER
stress,
research
provides
potential
strategy
for
preclinical
investigation
JCO Precision Oncology,
Journal Year:
2023,
Volume and Issue:
7
Published: June 1, 2023
PURPOSE
The
Targeted
Agent
and
Profiling
Utilization
Registry
Study
is
a
pragmatic
basket
trial
evaluating
antitumor
activity
of
commercially
available
targeted
agents
in
patients
with
advanced
cancers
harboring
potentially
actionable
genomic
alterations.
Data
from
cohort
lung
cancer
ERBB2
mutation
or
amplification
treated
pertuzumab
plus
trastuzumab
(P
+
T)
are
reported.
METHODS
Eligible
had
any
histology,
no
standard
treatment
options,
measurable
disease
(RECIST
v1.1),
Eastern
Cooperative
Oncology
Group
performance
status
0-2,
adequate
organ
function,
tumors
amplification.
Simon's
two-stage
design
was
used
primary
end
point
control
(DC),
defined
as
objective
response
(OR)
per
RECIST
v.
1.1
stable
(SD)
at
least
16
weeks
duration
(SD16+).
Secondary
points
included
safety,
response,
SD,
progression-free
survival,
overall
survival.
RESULTS
Twenty-eight
(27
non–small-cell,
1
small-cell)
(n
=
15),
12),
both
1)
were
enrolled
November
2016
to
July
2020.
All
evaluable
for
efficacy
toxicity.
Three
partial
(two
mutation;
one
amplification)
seven
SD16+
(five
two
observed
DC
rate
37%
(95%
CI,
21
50;
P
.005)
OR
11%
2
28).
Five
more
grade
3
4
adverse
serious
events
possibly
related
T.
CONCLUSION
Combination
T
showed
evidence
heavily
pretreated
non–small-cell
amplification,
particularly
those
exon
20
insertion
mutations.
Oncology and Therapy,
Journal Year:
2024,
Volume and Issue:
12(2), P. 223 - 231
Published: March 27, 2024
The
identification
of
actionable
biomarkers
and
development
targeted
therapies
have
revolutionized
the
field
lung
cancer
treatment.
In
patients
with
advanced
non-small
cell
(NSCLC),
biomarker
testing
can
inform
selection
effective
as
well
avoid
that
are
less
likely
to
be
in
certain
populations.
A
growing
number
targets,
including
those
involving
EGFR,
ALK,
ROS1,
BRAF,
MET,
KRAS,
NTRK,
RET,
HER2,
PD-L1,
identified
testing.
More
than
half
NSCLC
tumors
harbor
genetic
alterations
targeted.
When
these
treated
therapy,
survival
quality
life
may
significantly
improved.
addition,
broad-based
molecular
detect
identifying
who
potentially
eligible
for
current
or
future
clinical
trials.
Comprehensive
rates
communities
often
low,
turnaround
times
results
unacceptably
long.
There
is
an
unmet
need
widespread,
efficient,
routine
all
recommended
by
guidelines.
New
techniques
technologies
make
this
attainable
goal.
Panel-based
sequencing
platforms
becoming
more
accessible,
analysis
circulating
tumor
DNA
common.
podcast,
we
discuss
importance
explore
topics
such
methodologies,
effect
on
patient
outcomes,
emerging
technologies,
strategies
improving
United
States.
Supplementary
file1
(MP4
121301
KB).
Results
from
the
phase
III
Keynote-024
clinical
trial
have
established
Pembrolizumab
monotherapy
as
first-line
standard
of
care
for
patients
with
metastatic
NSCLC
who
PD-L1
expression
≥
50%,
EGFR
and
ALK
wild-type.
However,
given
differences
between
treated
in
routine
practice
within
a
trial,
real-world
data
are
needed
to
confirm
treatment
benefit
practice.
Given
lack
on
large
cohorts
long
follow-up,
we
designed
retrospective
observational
study
were
Pembrolizumab,
starting
its
reimbursement
eligibility
until
December
2020.
The
primary
endpoints
assess
PFS
OS
using
Kaplan-Meier
method,
response
safety.
We
followed
880
(median
follow-up:
35.1
months)
February
2022.
Median
8.6
months
(95%
CI:
7.6-10.0)
25.5
21.8-31.6),
respectively.
also
found
that
ECOG
PS,
smoking
habit
prognostic
factors
PFS,
while
age,
sex,
histology
had
an
impact
OS.
Multivariable
analysis
confirms
role
both
39.9%
reported
adverse
event,
but
only
6.3%
discontinued
therapy
due
toxicity.
Our
results
suggest
long-term
setting
well
safety
profile
consistent
Keynote-042.
Many
collected
variables
appear
influence
outcome,
these
exploratory
unadjusted
analyses
should
be
interpreted
caution.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(21), P. 11354 - 11354
Published: Oct. 22, 2024
Molecular
testing
is
recommended
in
patients
with
metastatic
non-small
cell
lung
cancer
(NSCLC),
but
the
extent
of
its
use
Poland
unknown.
The
aim
POL-MOL
study
was
to
investigate
frequency
using
molecular
Polish
NSCLC.
invited
oncologists
completed
two
questionnaires,
and
data
for
1001
undergoing
systemic
treatment
NSCLC
were
collected.
tests
following
genetic
mutations
recorded:
